ezogabine has been researched along with Peripheral Nerve Diseases in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dalby-Brown, W; Munro, G | 1 |
| Dang, D; Frost, JA; Li, J; Li, L; Yang, Q; Zuo, Y | 1 |
| Nodera, H; Rutkove, S; Spieker, A; Sung, M | 1 |
| Kaji, R | 1 |
| Dost, R; Rostock, A; Rundfeldt, C | 1 |
| Lerche, H; Maljevic, S; Wuttke, TV | 1 |
2 review(s) available for ezogabine and Peripheral Nerve Diseases
| Article | Year |
|---|---|
Kv7 (KCNQ) channel modulators and neuropathic pain.
Topics: Analgesics; Animals; Humans; Ion Channel Gating; KCNQ Potassium Channels; Pain; Peripheral Nervous System Diseases; Signal Transduction | 2007 |
Nervous system KV7 disorders: breakdown of a subthreshold brake.
Topics: Anticonvulsants; Carbamates; Epilepsy, Benign Neonatal; Humans; KCNQ Potassium Channels; Mutation; Nervous System Diseases; Peripheral Nervous System Diseases; Phenylenediamines | 2008 |
4 other study(ies) available for ezogabine and Peripheral Nerve Diseases
| Article | Year |
|---|---|
Activation of KCNQ Channels Prevents Paclitaxel-Induced Peripheral Neuropathy and Associated Neuropathic Pain.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carbamates; Cell Line, Tumor; Drug Repositioning; Humans; KCNQ Potassium Channels; Male; Neuralgia; Neurons; Neuroprotective Agents; Paclitaxel; Peripheral Nervous System Diseases; Phenylenediamines; Random Allocation; Rats, Sprague-Dawley | 2019 |
Neuroprotective effects of Kv7 channel agonist, retigabine, for cisplatin-induced peripheral neuropathy.
Topics: Action Potentials; Animals; Carbamates; Cisplatin; Disease Models, Animal; Drug Interactions; Injections, Intraperitoneal; Male; Mice; Neural Conduction; Neuroprotective Agents; Peripheral Nervous System Diseases; Phenylenediamines; Potassium Channel Blockers; Time Factors | 2011 |
A potassium channel opener for neuropathy, motor neuron disease and beyond.
Topics: Animals; Carbamates; Cisplatin; Male; Neuroprotective Agents; Peripheral Nervous System Diseases; Phenylenediamines; Potassium Channel Blockers | 2011 |
The anti-hyperalgesic activity of retigabine is mediated by KCNQ potassium channel activation.
Topics: Acute Disease; Amines; Analgesics, Opioid; Animals; Carbamates; Cyclohexanecarboxylic Acids; Disease Models, Animal; Dose-Response Relationship, Drug; Gabapentin; gamma-Aminobutyric Acid; Hyperalgesia; Indoles; Ion Channel Gating; KCNQ2 Potassium Channel; KCNQ3 Potassium Channel; Male; Mice; Peripheral Nervous System Diseases; Phenylenediamines; Physical Stimulation; Potassium Channel Blockers; Potassium Channels, Voltage-Gated; Pyridines; Rats; Rats, Wistar; Spinal Nerves; Touch; Tramadol | 2004 |